Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced at a Commercial Scale in Subjects Aged 40 Years and Older.

Authors not listed

MAXVAX Biotechnology Limited Liability Company · 2024

Abstract

To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-25 MST

Cite this

APA
Anonymous. (2024). A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced at a Commercial Scale in Subjects Aged 40 Years and Older. <em>MAXVAX Biotechnology Limited Liability Company</em>. https://clinicaltrials.gov/study/NCT06654700
Vancouver
Anonymous. A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced at a Commercial Scale in Subjects Aged 40 Years and Older. MAXVAX Biotechnology Limited Liability Company. 2024.
BibTeX
@misc{anon2024ARando, title = {A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced at a Commercial Scale in Subjects Aged 40 Years and Older.}, author = {Anonymous}, journal = {MAXVAX Biotechnology Limited Liability Company}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings